CoChat
Sign Up
Cited by 70Extracellular vesicles in diseaseLiver Disease Diagnosis and TreatmentMicroRNA in disease regulation

Adipose-derived mesenchymal stem cell-secreted extracellular vesicles alleviate non-alcoholic fatty liver disease via delivering miR-223-3p

Open access
Niu, Qinghui, Wang, Ting, Wang, Zhiqiang, Wang, Feng, Huang, Deyu, Sun, Huali, Liu, Hanyun·2022·Adipocyte
DOI 10.1080/21623945.2022.2098583PMC PMC9481107
Open this paper in CoChat — free account

Abstract

Increasing studies have identified the potential of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) in non-alcoholic fatty liver disease (NAFLD) treatment. Hence, we further focused on the potential of adipose-derived MSC (ADSC)-EVs in NAFLD by delivering miR-223-3p. The uptake of isolated ADSC-EVs by hepatocytes was assessed, and the expression of miR-223-3p in ADSC-EVs and hepatocytes was characterized. It was established that miR-223-3p, enriched in ADSC-EVs, could be delivered by ADSC-EVs into hepatocytes. Using co-culture system and gain-of-function approach, we evaluated the effect of ADSC-EVs carrying miR-223-3p on lipid accumulation and liver fibrosis in pyrrolizidine alkaloids (PA)-induced hepatocytes and a high-fat diet-induced NAFLD mouse model. Bioinformatics websites and dual-luciferase reporter gene assay were performed to determine the interactions between miR-223-3p and E2F1, which was further validated by rescue experiments. ADSC-EVs containing miR-223-3p displayed suppressive effects on lipid accumulation and liver fibrosis through E2F1 inhibition, since E2F1 was demonstrated as a target gene of miR-223-3p. The protective role of ADSC-EVs by delivering miR-223-3p was then confirmed in the mouse model. Collectively, this study elucidated that ADSC-EVs delayed the progression NAFLD through the delivery of anti-fibrotic miR-223-3p and subsequent E2F1 suppression, which may suggest miR-223-3p-loaded ADSC-EVs to be a potential therapeutic approach for NAFLD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21623945.2022.2098583

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 46

  1. [1]Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021; 397(10290): 2212– 2224. 33894145
  2. [2]Ruissen MM, Mak AL, Beuers U, et al. Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease. Eur J Endocrinol. 2020; 183(3): R57– R73. 32508312
  3. [3]Tanaka N, Kimura T, Fujimori N, et al. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol. 2019; 25(2): 163– 177. 30670907 PMC6337019
  4. [5]Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015; 62(3): 720– 733. 25450203
  5. [6]Rostom DM, Attia N, Khalifa HM, et al. The therapeutic potential of extracellular vesicles versus mesenchymal stem cells in liver damage. Tissue Eng Regen Med. 2020; 17(4): 537– 552. 32506351 PMC7393001
  6. [7]Zhao M, Liu S, Wang C, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate mitochondrial damage and inflammation by stabilizing mitochondrial DNA. ACS Nano. 2021; 15(1): 1519– 1538. 33369392
  7. [8]Phinney DG, Di Giuseppe M, Njah J, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat Commun. 2015; 6(8472). DOI: 10.1038/ncomms9472. PMC4598952 26442449 · DOI · Paper page
  8. [9]Su T, Xiao Y, Xiao Y, et al. Bone Marrow mesenchymal stem cells-derived exosomal MiR-29b-3p Regulates aging-associated insulin resistance. ACS Nano. 2019; 13(2): 2450– 2462. 30715852
  9. [10]Qiu G, Zheng G, Ge M, et al. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs. Stem Cell Res Ther. 2018; 9(1): 320. 30463593 PMC6249826
  10. [11]Ritter A, Friemel A, Roth S, et al. Subcutaneous and visceral adipose-derived mesenchymal stem cells: commonality and diversity. Cells. 2019; 8(10): 1288. PMC6830091 31640218
  11. [12]Louwen F, Ritter A, Kreis NN, et al. Insight into the development of obesity: functional alterations of adipose-derived mesenchymal stem cells. Obes Rev. 2018; 19(7): 888– 904. 29521029
  12. [13]Yano M, Nasti A, Seki A, et al. Characterization of adipose tissue-derived stromal cells of mice with nonalcoholic fatty liver disease and their use for liver repair. Regen Ther. 2021; 18: 497– 507. 34926735 PMC8649123
  13. [14]Urabe F, Kosaka N, Ito K, et al. Extracellular vesicles as biomarkers and therapeutic targets for cancer. Am J Physiol Cell Physiol. 2020; 318(1): C29– C39. 31693397
  14. [15]Kuang Y, Zheng X, Zhang L, et al. Adipose-derived mesenchymal stem cells reduce autophagy in stroke mice by extracellular vesicle transfer of miR-25. J Extracell Vesicles. 2020; 10(1): e12024. 33304476 PMC7710129
  15. [16]Shao H, Im H, Castro CM, et al. New technologies for analysis of extracellular vesicles. Chem Rev. 2018; 118(4): 1917– 1950. 29384376 PMC6029891
  16. [17]O’Brien K, Breyne K, Ughetto S, et al. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020; 21(10): 585– 606. 32457507 PMC7249041
  17. [18]Wu D, Zhu H, Wang H. Extracellular vesicles in non-alcoholic fatty liver disease and alcoholic liver disease. Front Physiol. 2021; 12: 707429. 34335310 PMC8316622
  18. [19]Dorairaj V, Sulaiman SA, Abu N, et al. Extracellular vesicles in the development of the non-alcoholic fatty liver disease: an update. Biomolecules. 2020; 10(11): 1494. PMC7693409 33143043
  19. [20]Liu XL, Pan Q, Cao HX, et al. Lipotoxic hepatocyte-derived exosomal MicroRNA 192-5p activates macrophages through rictor/akt/forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease. Hepatology. 2020; 72(2): 454– 469. 31782176 PMC10465073
  20. [21]Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008; 451(7182): 1125– 1129. 18278031
  21. [22]Ye D, Zhang T, Lou G, et al. Role of miR-223 in the pathophysiology of liver diseases. Exp Mol Med. 2018; 50(9): 1– 12. PMC6158210 30258086
  22. [23]Jimenez Calvente C, Del Pilar H, Tameda M, et al. MicroRNA 223 3p negatively regulates the NLRP3 inflammasome in acute and chronic liver injury. Mol Ther. 2020; 28(2): 653– 663. 31585800 PMC7000998
  23. [24]Lu FB, Chen DZ, Chen L, et al. Attenuation of experimental autoimmune hepatitis in mice with bone mesenchymal stem cell-derived exosomes carrying MicroRNA-223-3p. Mol Cells. 2019; 42(12): 906– 918. 31826604 PMC6939658
  24. [25]Aziz F. The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders. Cell Immunol. 2016; 303: 1– 6. 27129807
  25. [26]Zhang Y, Xu N, Xu J, et al. E2F1 is a novel fibrogenic gene that regulates cholestatic liver fibrosis through the Egr-1/SHP/EID1 network. Hepatology. 2014; 60(3): 919– 930. 24619556 PMC4146672
  26. [27]Lin CS, Lin FY, Ho LJ, et al. PKCdelta signalling regulates SR-A and CD36 expression and foam cell formation. Cardiovasc Res. 2012; 95(3): 346– 355. 22687273
  27. [28]Liu Y, Xu W, Zhai T, et al. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm Sin B. 2019; 9(4): 745– 757. 31384535 PMC6664044
  28. [29]Flores-Costa R, Alcaraz-Quiles J, Titos E, et al. The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. Br J Pharmacol. 2018; 175(6): 953– 967. 29281143 PMC5825296
  29. [31]Chen L, Lu FB, Chen DZ, et al. BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis. Mol Immunol. 2018; 93: 38– 46. 29145157
  30. [32]Baranova A, Maltseva D, Tonevitsky A. Adipose may actively delay progression of NAFLD by releasing tumor-suppressing, anti-fibrotic miR-122 into circulation. Obes Rev. 2019; 20(1): 108– 118. 30248223
  31. [33]Alamri H, Patterson NH, Yang E, et al. Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis. Anal Bioanal Chem. 2019; 411(4): 885– 894. 30515538 PMC6513670
  32. [34]Rana R, Shearer AM, Fletcher EK, et al. PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. Mol Metab. 2019; 29: 99– 113. 31668396 PMC6742970
  33. [35]Sun CC, Zhang CY, Duan JX, et al. PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice. Biochem Biophys Res Commun. 2020; 523(4): 1020– 1026. 31973813 PMC7990110
  34. [36]Zhao W, Wang X, Sun KH, et al. Alpha-smooth muscle actin is not a marker of fibrogenic cell activity in skeletal muscle fibrosis. PLoS One. 2018; 13(1): e0191031. 29320561 PMC5761950
  35. [37]Liu SB, Ikenaga N, Peng ZW, et al. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. FASEB J. 2016; 30(4): 1599– 1609. 26700732
  36. [38]Mohagheghi S, Geramizadeh B, Nikeghbalian S, et al. Intricate role of yes-associated protein1 in human liver cirrhosis: TGF-β1 still is a giant player. IUBMB Life. 2019; 71(10): 1453– 1464. 31087779
  37. [39]Wei Z, Zhao D, Zhang Y, et al. Rosiglitazone ameliorates bile duct ligation-induced liver fibrosis by down-regulating NF-kappaB-TNF-alpha signaling pathway in a PPARgamma-dependent manner. Biochem Biophys Res Commun. 2019; 519(4): 854– 860. 31561855
  38. [40]Xie K, Chen CH, Tsai SP, et al. Loss of life expectancy by 10 years or more from elevated aspartate aminotransferase: finding aspartate aminotransferase a better mortality predictor for all-cause and liver-related than alanine aminotransferase. Am J Gastroenterol. 2019; 114(9): 1478– 1487. 31425154
  39. [41]Zhang M, Yuan Y, Wang Q, et al. The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKalpha. Biosci Rep. 2018; 38(6). DOI: 10.1042/BSR20180644. PMC6239269 30291215 · DOI
  40. [42]Patel V, Joharapurkar A, Kshirsagar S, et al. Coagonist of GLP-1 and glucagon receptor ameliorates development of non-alcoholic fatty liver disease. Cardiovasc Hematol Agents Med Chem. 2018; 16(1): 35– 43. 29357809
  41. [43]de Conti A, Ortega JF, Tryndyak V, et al. MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis. Oncotarget. 2017; 8(51): 88517– 88528. 29179453 PMC5687623
  42. [44]Denechaud PD, Lopez-Mejia IC, Giralt A, et al. E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis. J Clin Invest. 2016; 126(1): 137– 150. 26619117 PMC4701565
  43. [45]Szabo G, Momen-Heravi F. Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2017; 14(8): 455– 466. 28634412 PMC6380505
  44. [46]Devhare PB, Ray RB. Extracellular vesicles: novel mediator for cell to cell communications in liver pathogenesis. Mol Aspects Med. 2018; 60: 115– 122. 29122679 PMC5856598
  45. [47]Momen-Heravi F, Bala S, Bukong T, et al. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine. 2014; 10(7): 1517– 1527. 24685946 PMC4180003
  46. [48]Liu R, Li X, Zhu W, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. Hepatology. 2019; 70(4): 1317– 1335. 30985008 PMC6783323

Cited by

Sorted by citations

Authors
Niu, Q., Wang, T., Wang, Z., Wang, F., Huang, D., Sun, H., & Liu, H.
Affiliations
Affiliated Hospital of Qingdao University (CN)
Corresponding author
Liu, Hanyun
ORCID
Venue
Adipocyte
Publisher
Informa UK Limited
Published
2022-09-12
Volume
11
Issue
1
Pages
572-587
ISSN
  • 2162-3945 (ISSN-L)
  • 2162-397X
DOI
10.1080/21623945.2022.2098583
PMC
PMC9481107
OpenAlex
W4295259903
Cited by
70
References
2
Citations by year
2026: 16 · 2025: 22 · 2024: 19 · 2023: 11 · 2022: 2
FWCI
4.41
Type
journal article
Language
en
Open access
Licence
Locations
  • Adipocyte (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
there is no funding associated
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
adipose-derived stem cells, extracellular vesicles, non-alcoholic fatty liver disease, miR-223-3p, E2F1, liver fibrosis, hepatic lipid accumulation, pyrrolizidine alkaloids, high-fat diet, cell-free therapy, microRNA delivery
MeSH terms
Extracellular Vesicles, Animals, Lipids, Liver Cirrhosis, MicroRNAs, Mice, Mesenchymal Stem Cells, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review